Business Context and Reporting Period
Company: ZIMMER BIOMET HOLDINGS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2017
Subject: Resolution of previously disclosed U.S. Foreign Corrupt Practices Act (FCPA) matters involving Biomet, Inc. (acquired June 2015) and certain subsidiaries.
Key Financial Metrics and Settlement Costs
This filing details specific settlement payments rather than standard operating financial metrics (revenue, profit, cash flow). The filing does not provide current period revenue, profit, or liquidity data.
- SEC Civil Settlement Payments: $13,022,805 total (comprising $6,522,805 in disgorgement of profits with pre-judgment interest and a $6,500,000 civil penalty).
- DOJ Criminal Penalty: $17,460,300.
- Total Settlement Payments: $30,483,105.
- Payment Timing: Expected by the end of January 2017.
- Accounting Treatment: The Company accrued a sufficient amount to cover this matter as of June 24, 2015 (the acquisition closing date).
Material Changes and Legal Resolutions
The filing reports the finalization of three distinct legal agreements resolving FCPA violations that occurred prior to the Company's acquisition of Biomet, Inc.:
- SEC Order: Biomet, Inc. entered an administrative cease-and-desist order regarding violations of books and records, internal controls, and anti-bribery provisions.
- Deferred Prosecution Agreement (DPA): The Company entered a three-year DPA with the U.S. Department of Justice (DOJ) regarding internal controls violations. Prosecution will be dismissed with prejudice if the Company complies with terms.
- Plea Agreement: JERDS Luxembourg Holding S.à r.l. (a subsidiary) pleaded guilty to aiding and abetting a violation of the books and records provision. It will pay only a nominal assessment and no criminal penalty due to the Company's DPA.
Outlook, Risks, and Management Commentary
Compliance Oversight: The Company is subject to oversight by an independent compliance monitor for at least the first 12 months of the three-year DPA term. The monitor will focus on legacy Biomet operations integrated into the Company.
Extension Risk: The DOJ may extend the DPA term for up to one additional year at its discretion.
Forward-Looking Statements: The filing includes standard disclaimers that actual outcomes may differ materially from expectations due to risks and uncertainties.
Investor Verification Checklist
- Verify the impact of the $30.5 million settlement on the Company's cash position, noting the prior accrual in 2015.
- Review the full text of the Deferred Prosecution Agreement (Exhibit 10.1) for specific compliance requirements.
- Monitor the appointment and scope of the independent compliance monitor.
- Confirm that no additional penalties are expected beyond the amounts disclosed in this filing.